Experimental cell therapy for advanced lung cancer shows early promise but trial halted
NCT ID NCT06491225
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a personalized treatment called GTE-001, which uses immune cells taken from a patient's own tumor to attack their cancer. It was designed for people with advanced lung adenocarcinoma that had stopped responding to standard chemotherapy. However, the study was terminated after enrolling only 2 participants, so we have very limited information about its safety or effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Tumor-infiltrating lymphocytes (GTE-001 injection)
- What this could lead to
- If it works, this could point toward a new cell-based treatment for advanced lung adenocarcinoma that has stopped responding to standard chemotherapy.
- What could go wrong
- This was a very early, small trial (only 2 participants) that was terminated, so we have very little data. The approach is complex and may not work for most patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
2 people
The number who actually took part.
- Started
-
Jul 2024
- Finished
-
Aug 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 1\. Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol; * 2\. Age ≥18 years old; * 3\. Advanced lung adenocarcinoma that progresses after recurrence or first-line chemotherapy； * 4\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; * 5\. Expected survival time of ≥ 3 months; * 6\. Good function of vital organs; * 7\. At least one measurable target lesion that meets the definition of RECIST v1.1 after tumor sampling. Exclusion Criteria: * 1.Subject has previously received an allogeneic stem cell transplant or organ allograft,Subject has previously received engineered cell therapy,Prior FOLR1 directed therapy is not allowed unless it had been with an approved agent in the indication; * 2.Subject has undergone surgery or received radiotherapy, immunotherapy, targeted therapy agents, anticancer vaccines, systemic steroids, or chemotherapy within 2 weeks of enrolment. Targeted agents, such as tyrosine kinase inhibitors, may be continued until 5 half-lives before enrolment; * 3.Pregnant or lactating women; or women who are pregnant, breastfeeding, or planning to become pregnant within 12 months after cell infusion; * 4.History of central nervous system (CNS) disorder,History of autoimmune disease,History of primary immunodeficiency;
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced lung adenocarcinoma；adult are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 102200, China